Relmada Therapeutics Reinforces Balance Sheet with $15.2 Million from Exercise of Warrants

By WebmasterOctober 16, 2014November 1st, 2024No Comments

Relmada Therapeutics Reinforces Balance Sheet with $15.2 Million from Exercise of Warrants
Read more here

Previous PostRelmada Therapeutics Appoints Michael Becker as Senior Vice President of Finance and Corporate Development
Next PostHealthQx Partners with HCI3, Leader in Value-based Payment Reform